Share Price and Basic Stock Data
Last Updated: November 11, 2025, 7:53 pm
| PEG Ratio | -1.01 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Elixir Capital Ltd, operating in the Finance & Investments sector, reported a current market capitalization of ₹68.4 Cr and a share price of ₹118. The company has experienced fluctuating revenue trends over recent quarters, with sales standing at ₹4.75 Cr in June 2023, rising to ₹6.09 Cr by September 2023, and further increasing to ₹15.81 Cr by March 2024. However, revenue dipped to ₹4.32 Cr for FY 2023, reflecting a significant decline from the ₹24.53 Cr recorded in FY 2022. The trailing twelve months (TTM) revenue is reported at ₹31.56 Cr, indicating a recovery trajectory. Analyzing the quarterly sales, it is notable that the company faced negative sales in several quarters, underscoring a volatile revenue environment. The company’s ability to navigate these challenges will be critical in maintaining growth in a competitive sector, where financial institutions typically strive for consistent performance.
Profitability and Efficiency Metrics
Elixir Capital’s profitability metrics illustrate a mixed performance landscape. The company reported an operating profit margin (OPM) of 38.92%, which, while commendable, has fluctuated significantly across reporting periods, peaking at 84.76% in March 2024 before declining to 38.92% in June 2025. Net profit for FY 2025 stood at ₹12.65 Cr, marking a recovery from the net loss of ₹3.43 Cr in FY 2023. The return on equity (ROE) is recorded at 18.0%, while the return on capital employed (ROCE) is at 20.1%, both of which are strong indicators of the company’s efficiency in generating returns relative to shareholder equity and capital employed. However, the interest coverage ratio (ICR) of 10.26 times indicates a solid capacity to meet interest obligations, further enhancing the company’s financial stability amidst operating challenges.
Balance Sheet Strength and Financial Ratios
Elixir Capital’s balance sheet reflects a robust financial structure, with total assets amounting to ₹115.59 Cr as of March 2025. The company reported reserves of ₹50.97 Cr and borrowings of ₹31.32 Cr, leading to a debt-to-equity ratio of 0.55, suggesting a moderate leverage position. The price-to-book value (P/BV) ratio stands at 1.38x, indicating that the stock is trading at a premium compared to its book value, which is ₹97.83 per share. The current ratio of 2.37x signifies a strong liquidity position, while the quick ratio of 0.70x highlights potential challenges in covering short-term liabilities without selling inventory. The return on assets (ROA) is reported at 8.06%, which is relatively healthy compared to industry standards, suggesting efficient asset utilization despite the company’s recent operational fluctuations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Elixir Capital indicates a strong promoter presence, with promoters holding 71.29% of the equity. This significant stake suggests confidence from the management in the company’s strategic direction. The public holds 28.72% of shares, with the number of shareholders reported at 4,227 as of March 2025, reflecting a slight increase from previous quarters. This stability in shareholder composition is crucial for maintaining investor confidence, particularly in a sector characterized by volatility. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may signal a lack of broader institutional interest, which could impact the stock’s liquidity and market perception. The concentrated shareholding by promoters may also raise concerns regarding governance and decision-making transparency, which are essential for attracting institutional investments.
Outlook, Risks, and Final Insight
Looking ahead, Elixir Capital faces both opportunities and risks. The company has shown potential for revenue recovery, particularly with the substantial sales increase reported in March 2024. However, the historical volatility in sales and profitability metrics poses a risk to sustained growth. The high promoter holding can be a double-edged sword, providing stability but potentially limiting broader market participation. Risks also include the company’s dependency on market conditions, which can affect its financial performance. Furthermore, the absence of institutional investors may hinder the stock’s growth potential in the long term. To navigate these challenges, Elixir Capital must focus on improving operational efficiency and enhancing investor engagement to foster a more diversified ownership structure. The company’s ability to adapt to market dynamics will be crucial for its future performance and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Elixir Capital Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Monarch Networth Capital Ltd | 2,419 Cr. | 305 | 484/280 | 15.7 | 102 | 0.33 % | 33.3 % | 26.2 % | 10.0 |
| Monotype India Ltd | 37.3 Cr. | 0.53 | 2.42/0.46 | 3.62 | 0.02 | 0.00 % | 286 % | % | 1.00 |
| Multipurpose Trading & Agencies Ltd | 4.14 Cr. | 8.36 | 12.6/8.25 | 10.3 | 0.00 % | 3.68 % | 3.38 % | 10.0 | |
| Munoth Financial Services Ltd | 30.2 Cr. | 58.8 | 72.0/47.6 | 20.6 | 0.00 % | 2.41 % | 3.38 % | 10.0 | |
| Naperol Investments Ltd | 488 Cr. | 849 | 1,630/0.00 | 50.7 | 2,055 | 1.06 % | 1.06 % | 0.95 % | 10.0 |
| Industry Average | 6,833.68 Cr | 1,391.53 | 108.28 | 3,866.53 | 0.33% | 21.83% | 14.30% | 7.26 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -3.53 | 7.80 | 0.08 | -0.60 | 4.75 | 6.09 | 5.91 | 15.81 | 14.72 | 18.56 | 6.04 | -3.96 | 10.92 |
| Expenses | 1.34 | 1.53 | 1.31 | 1.51 | 1.57 | 1.68 | 1.62 | 2.41 | 3.04 | 3.00 | 3.70 | 5.59 | 6.67 |
| Operating Profit | -4.87 | 6.27 | -1.23 | -2.11 | 3.18 | 4.41 | 4.29 | 13.40 | 11.68 | 15.56 | 2.34 | -9.55 | 4.25 |
| OPM % | 80.38% | -1,537.50% | 66.95% | 72.41% | 72.59% | 84.76% | 79.35% | 83.84% | 38.74% | 38.92% | |||
| Other Income | 0.28 | 0.05 | 0.17 | 0.24 | 0.34 | 0.89 | 0.22 | 1.20 | 0.27 | 0.16 | 0.22 | -0.13 | 1.17 |
| Interest | 0.22 | 0.28 | 0.33 | 0.30 | 0.34 | 0.40 | 0.33 | 0.45 | 0.43 | 0.56 | 0.66 | 0.38 | 0.62 |
| Depreciation | 0.07 | 0.08 | 0.08 | 0.10 | 0.08 | 0.09 | 0.08 | 0.09 | 0.07 | 0.09 | 0.08 | 0.26 | 0.11 |
| Profit before tax | -4.88 | 5.96 | -1.47 | -2.27 | 3.10 | 4.81 | 4.10 | 14.06 | 11.45 | 15.07 | 1.82 | -10.32 | 4.69 |
| Tax % | 1.43% | 6.04% | -2.72% | 16.74% | 1.61% | 15.38% | 22.44% | 24.32% | 24.98% | 25.08% | 34.62% | -18.22% | 21.54% |
| Net Profit | -4.95 | 5.61 | -1.43 | -2.65 | 3.06 | 4.08 | 3.19 | 10.63 | 8.59 | 11.30 | 1.19 | -8.44 | 3.69 |
| EPS in Rs | -8.53 | 28.98 | -1.77 | -3.38 | 3.89 | 5.39 | 4.07 | 13.54 | 10.94 | 14.41 | 1.52 | -10.80 | 4.70 |
Last Updated: August 19, 2025, 3:48 pm
Below is a detailed analysis of the quarterly data for Elixir Capital Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 10.92 Cr.. The value appears strong and on an upward trend. It has increased from -3.96 Cr. (Mar 2025) to 10.92 Cr., marking an increase of 14.88 Cr..
- For Expenses, as of Jun 2025, the value is 6.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.59 Cr. (Mar 2025) to 6.67 Cr., marking an increase of 1.08 Cr..
- For Operating Profit, as of Jun 2025, the value is 4.25 Cr.. The value appears strong and on an upward trend. It has increased from -9.55 Cr. (Mar 2025) to 4.25 Cr., marking an increase of 13.80 Cr..
- For OPM %, as of Jun 2025, the value is 38.92%. The value appears strong and on an upward trend. It has increased from 0.00% (Mar 2025) to 38.92%, marking an increase of 38.92%.
- For Other Income, as of Jun 2025, the value is 1.17 Cr.. The value appears strong and on an upward trend. It has increased from -0.13 Cr. (Mar 2025) to 1.17 Cr., marking an increase of 1.30 Cr..
- For Interest, as of Jun 2025, the value is 0.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.38 Cr. (Mar 2025) to 0.62 Cr., marking an increase of 0.24 Cr..
- For Depreciation, as of Jun 2025, the value is 0.11 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.26 Cr. (Mar 2025) to 0.11 Cr., marking a decrease of 0.15 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.69 Cr.. The value appears strong and on an upward trend. It has increased from -10.32 Cr. (Mar 2025) to 4.69 Cr., marking an increase of 15.01 Cr..
- For Tax %, as of Jun 2025, the value is 21.54%. The value appears to be increasing, which may not be favorable. It has increased from -18.22% (Mar 2025) to 21.54%, marking an increase of 39.76%.
- For Net Profit, as of Jun 2025, the value is 3.69 Cr.. The value appears strong and on an upward trend. It has increased from -8.44 Cr. (Mar 2025) to 3.69 Cr., marking an increase of 12.13 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.70. The value appears strong and on an upward trend. It has increased from -10.80 (Mar 2025) to 4.70, marking an increase of 15.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:26 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.86 | 11.70 | 4.45 | 12.41 | 10.15 | 3.70 | -0.40 | 19.62 | 24.53 | 4.32 | 34.63 | 36.07 | 31.56 |
| Expenses | 1.71 | 1.81 | 2.26 | 2.64 | 3.76 | 3.36 | 3.73 | 4.61 | 5.53 | 5.70 | 7.25 | 15.33 | 18.96 |
| Operating Profit | 2.15 | 9.89 | 2.19 | 9.77 | 6.39 | 0.34 | -4.13 | 15.01 | 19.00 | -1.38 | 27.38 | 20.74 | 12.60 |
| OPM % | 55.70% | 84.53% | 49.21% | 78.73% | 62.96% | 9.19% | 76.50% | 77.46% | -31.94% | 79.06% | 57.50% | 39.92% | |
| Other Income | 0.00 | 0.00 | 1.54 | 0.04 | 0.10 | 0.06 | 0.05 | 0.02 | 0.03 | 0.18 | 0.56 | -0.19 | 1.42 |
| Interest | 0.06 | 0.05 | 0.07 | 0.13 | 0.15 | 0.25 | 0.19 | 0.95 | 1.66 | 1.13 | 1.52 | 2.03 | 2.22 |
| Depreciation | 0.50 | 0.47 | 0.46 | 0.48 | 0.47 | 0.45 | 0.40 | 0.41 | 0.37 | 0.34 | 0.34 | 0.50 | 0.54 |
| Profit before tax | 1.59 | 9.37 | 3.20 | 9.20 | 5.87 | -0.30 | -4.67 | 13.67 | 17.00 | -2.67 | 26.08 | 18.02 | 11.26 |
| Tax % | 29.56% | 29.35% | 24.38% | 25.00% | 28.28% | -10.00% | 10.49% | 10.53% | 23.65% | 28.46% | 19.63% | 29.86% | |
| Net Profit | 1.11 | 6.61 | 2.41 | 6.90 | 4.21 | -0.21 | -3.83 | 12.22 | 12.99 | -3.43 | 20.96 | 12.65 | 7.74 |
| EPS in Rs | 1.40 | 8.43 | 2.89 | 11.89 | 5.36 | -0.36 | -6.60 | 15.72 | 16.54 | -5.91 | 26.90 | 16.08 | 9.83 |
| Dividend Payout % | 121.31% | 20.16% | 11.74% | 10.51% | 23.31% | -345.24% | -18.93% | 7.95% | 7.55% | -21.14% | 4.64% | 7.77% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 495.50% | -63.54% | 186.31% | -38.99% | -104.99% | -1723.81% | 419.06% | 6.30% | -126.40% | 711.08% | -39.65% |
| Change in YoY Net Profit Growth (%) | 0.00% | -559.04% | 249.85% | -225.29% | -66.00% | -1618.82% | 2142.87% | -412.76% | -132.71% | 837.48% | -750.73% |
Elixir Capital Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | % |
| 3 Years: | 14% |
| TTM: | -26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 35% |
| 3 Years: | 0% |
| TTM: | -69% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 39% |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 21% |
| 3 Years: | 17% |
| Last Year: | 18% |
Last Updated: September 5, 2025, 3:21 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 8.51 | 0.00 | 0.82 | 3.24 | 5.75 | 1.97 | -2,646.25 | 0.37 | 5.21 | 21.12 | 2.42 | 0.81 |
| Inventory Days | -7,418.62 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 8.51 | 0.00 | 0.82 | 3.24 | 5.75 | 1.97 | -10,064.88 | 0.37 | 5.21 | 21.12 | 2.42 | 0.81 |
| Working Capital Days | 748.91 | 442.37 | 1,232.80 | 648.53 | 929.94 | 2,434.65 | 3,102.50 | 388.25 | 431.07 | 1,684.75 | 598.25 | 697.42 |
| ROCE % | 7.44% | 38.27% | 6.27% | 29.05% | 16.35% | -0.13% | -13.23% | 32.98% | 29.06% | -2.45% | 36.75% | 20.07% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.07 | 26.89 | -4.20 | 16.54 | 15.72 |
| Diluted EPS (Rs.) | 16.07 | 26.89 | -4.20 | 16.54 | 15.72 |
| Cash EPS (Rs.) | 22.64 | 36.70 | -5.32 | 23.00 | 21.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 97.83 | 117.55 | 83.14 | 90.74 | 70.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 97.83 | 117.55 | 83.14 | 90.74 | 70.07 |
| Revenue From Operations / Share (Rs.) | 60.94 | 56.07 | 6.48 | 39.92 | 33.12 |
| PBDIT / Share (Rs.) | 35.96 | 47.25 | -2.06 | 32.80 | 25.90 |
| PBIT / Share (Rs.) | 35.10 | 46.67 | -2.64 | 32.17 | 25.19 |
| PBT / Share (Rs.) | 31.06 | 44.94 | -4.59 | 29.30 | 23.55 |
| Net Profit / Share (Rs.) | 21.78 | 36.11 | -5.90 | 22.37 | 21.07 |
| NP After MI And SOA / Share (Rs.) | 16.07 | 26.89 | -4.20 | 16.54 | 15.72 |
| PBDIT Margin (%) | 59.00 | 84.27 | -31.82 | 82.16 | 78.20 |
| PBIT Margin (%) | 57.60 | 83.23 | -40.75 | 80.58 | 76.05 |
| PBT Margin (%) | 50.95 | 80.14 | -70.85 | 73.40 | 71.10 |
| Net Profit Margin (%) | 35.74 | 64.40 | -91.11 | 56.04 | 63.62 |
| NP After MI And SOA Margin (%) | 26.37 | 47.96 | -64.80 | 41.42 | 47.47 |
| Return on Networth / Equity (%) | 16.42 | 32.22 | -7.20 | 25.76 | 31.86 |
| Return on Capital Employeed (%) | 25.40 | 39.68 | -3.17 | 35.43 | 35.89 |
| Return On Assets (%) | 8.06 | 16.19 | -3.60 | 11.61 | 12.52 |
| Total Debt / Equity (X) | 0.55 | 0.48 | 0.21 | 0.47 | 0.60 |
| Asset Turnover Ratio (%) | 0.33 | 0.39 | 0.05 | 0.29 | 0.34 |
| Current Ratio (X) | 2.37 | 2.52 | 2.81 | 2.31 | 1.91 |
| Quick Ratio (X) | 0.70 | 0.58 | 1.20 | 0.95 | 0.82 |
| Inventory Turnover Ratio (X) | 0.62 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 10.59 | 6.32 | -40.54 | 10.29 | 11.05 |
| Dividend Payout Ratio (CP) (%) | 10.05 | 6.19 | -47.02 | 9.91 | 10.58 |
| Earning Retention Ratio (%) | 89.41 | 93.68 | 140.54 | 89.71 | 88.95 |
| Cash Earning Retention Ratio (%) | 89.95 | 93.81 | 147.02 | 90.09 | 89.42 |
| Interest Coverage Ratio (X) | 10.26 | 18.02 | -1.06 | 11.44 | 15.81 |
| Interest Coverage Ratio (Post Tax) (X) | 7.37 | 14.43 | -2.03 | 8.80 | 13.86 |
| Enterprise Value (Cr.) | 121.71 | 85.03 | 30.51 | 39.19 | 32.72 |
| EV / Net Operating Revenue (X) | 3.44 | 2.61 | 8.11 | 1.69 | 1.70 |
| EV / EBITDA (X) | 5.83 | 3.10 | -25.50 | 2.06 | 2.18 |
| MarketCap / Net Operating Revenue (X) | 2.21 | 1.58 | 5.28 | 0.95 | 0.86 |
| Retention Ratios (%) | 89.40 | 93.67 | 140.54 | 89.70 | 88.94 |
| Price / BV (X) | 1.38 | 1.06 | 0.58 | 0.59 | 0.57 |
| Price / Net Operating Revenue (X) | 2.21 | 1.58 | 5.28 | 0.95 | 0.86 |
| EarningsYield | 0.11 | 0.30 | -0.12 | 0.43 | 0.54 |
After reviewing the key financial ratios for Elixir Capital Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 16.07, marking a decrease of 10.82.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 16.07, marking a decrease of 10.82.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.64. This value is within the healthy range. It has decreased from 36.70 (Mar 24) to 22.64, marking a decrease of 14.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 97.83. It has decreased from 117.55 (Mar 24) to 97.83, marking a decrease of 19.72.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 97.83. It has decreased from 117.55 (Mar 24) to 97.83, marking a decrease of 19.72.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 60.94. It has increased from 56.07 (Mar 24) to 60.94, marking an increase of 4.87.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 35.96. This value is within the healthy range. It has decreased from 47.25 (Mar 24) to 35.96, marking a decrease of 11.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 35.10. This value is within the healthy range. It has decreased from 46.67 (Mar 24) to 35.10, marking a decrease of 11.57.
- For PBT / Share (Rs.), as of Mar 25, the value is 31.06. This value is within the healthy range. It has decreased from 44.94 (Mar 24) to 31.06, marking a decrease of 13.88.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 21.78. This value is within the healthy range. It has decreased from 36.11 (Mar 24) to 21.78, marking a decrease of 14.33.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 16.07. This value is within the healthy range. It has decreased from 26.89 (Mar 24) to 16.07, marking a decrease of 10.82.
- For PBDIT Margin (%), as of Mar 25, the value is 59.00. This value is within the healthy range. It has decreased from 84.27 (Mar 24) to 59.00, marking a decrease of 25.27.
- For PBIT Margin (%), as of Mar 25, the value is 57.60. This value exceeds the healthy maximum of 20. It has decreased from 83.23 (Mar 24) to 57.60, marking a decrease of 25.63.
- For PBT Margin (%), as of Mar 25, the value is 50.95. This value is within the healthy range. It has decreased from 80.14 (Mar 24) to 50.95, marking a decrease of 29.19.
- For Net Profit Margin (%), as of Mar 25, the value is 35.74. This value exceeds the healthy maximum of 10. It has decreased from 64.40 (Mar 24) to 35.74, marking a decrease of 28.66.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 26.37. This value exceeds the healthy maximum of 20. It has decreased from 47.96 (Mar 24) to 26.37, marking a decrease of 21.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.42. This value is within the healthy range. It has decreased from 32.22 (Mar 24) to 16.42, marking a decrease of 15.80.
- For Return on Capital Employeed (%), as of Mar 25, the value is 25.40. This value is within the healthy range. It has decreased from 39.68 (Mar 24) to 25.40, marking a decrease of 14.28.
- For Return On Assets (%), as of Mar 25, the value is 8.06. This value is within the healthy range. It has decreased from 16.19 (Mar 24) to 8.06, marking a decrease of 8.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.48 (Mar 24) to 0.55, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.33. It has decreased from 0.39 (Mar 24) to 0.33, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 2.37. This value is within the healthy range. It has decreased from 2.52 (Mar 24) to 2.37, marking a decrease of 0.15.
- For Quick Ratio (X), as of Mar 25, the value is 0.70. This value is below the healthy minimum of 1. It has increased from 0.58 (Mar 24) to 0.70, marking an increase of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.62. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.62, marking an increase of 0.62.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 10.59. This value is below the healthy minimum of 20. It has increased from 6.32 (Mar 24) to 10.59, marking an increase of 4.27.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 10.05. This value is below the healthy minimum of 20. It has increased from 6.19 (Mar 24) to 10.05, marking an increase of 3.86.
- For Earning Retention Ratio (%), as of Mar 25, the value is 89.41. This value exceeds the healthy maximum of 70. It has decreased from 93.68 (Mar 24) to 89.41, marking a decrease of 4.27.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 89.95. This value exceeds the healthy maximum of 70. It has decreased from 93.81 (Mar 24) to 89.95, marking a decrease of 3.86.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.26. This value is within the healthy range. It has decreased from 18.02 (Mar 24) to 10.26, marking a decrease of 7.76.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.37. This value is within the healthy range. It has decreased from 14.43 (Mar 24) to 7.37, marking a decrease of 7.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 121.71. It has increased from 85.03 (Mar 24) to 121.71, marking an increase of 36.68.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.44. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.44, marking an increase of 0.83.
- For EV / EBITDA (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has increased from 3.10 (Mar 24) to 5.83, marking an increase of 2.73.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.21, marking an increase of 0.63.
- For Retention Ratios (%), as of Mar 25, the value is 89.40. This value exceeds the healthy maximum of 70. It has decreased from 93.67 (Mar 24) to 89.40, marking a decrease of 4.27.
- For Price / BV (X), as of Mar 25, the value is 1.38. This value is within the healthy range. It has increased from 1.06 (Mar 24) to 1.38, marking an increase of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 2.21, marking an increase of 0.63.
- For EarningsYield, as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.11, marking a decrease of 0.19.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Elixir Capital Ltd:
- Net Profit Margin: 35.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 25.4% (Industry Average ROCE: 21.83%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.42% (Industry Average ROE: 14.3%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.37
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.7
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 9.97 (Industry average Stock P/E: 108.28)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.55
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 35.74%